Peptide Decoding
New?New to peptides?Start here →
Decoding

Peceleganan (PL-5)_Dosage, benefits & legal status

Also known as PL-5, PL5, Puyike, Pu Yi Ke, peceleganan spray, 培西加南

Published November 21, 2026

The first antimicrobial peptide to reach a national approval for wound infection, with a result that needs reading twice.

Clear infection in a woundSynthetic 26-residue antimicrobial peptide (topical spray)Clinical use
Dose2 parts per thousand spray, once daily (trials)
FrequencyOnce daily for up to 14 days (trial schedules)
RouteOn the skin (topical spray)
StatusApproved in China, not approved in the United States
CycledA short daily course, 8 to 14 days

See how this dose compares across the library →

01

What is Peceleganan (PL-5)?

Plain language first. The technical label stays, but it never stands alone.

Overview

A spray-on peptide for infected burns, approved in China, that works by breaking bacterial membranes.

The technical version

A 26-residue amphipathic alpha-helical cecropin-melittin hybrid analog, applied as a 2 permille topical spray for secondary wound infection, approved in China in June 2026.

What it's used for

A topical spray for wound infections secondary to first-degree and superficial second-degree burns and scalds, approved in China and not in the United States.

02

How does Peceleganan (PL-5) work?

What it does in the body, and where.

Antibiotics mostly work by jamming a specific bacterial process: building a wall, copying DNA, making protein. Resistance follows because a single change to that target can break the drug. Peceleganan does something cruder. It is positively charged and partly greasy, and it tears into the bacterial membrane itself.

  1. 01
    It is a hybrid of two natural peptides, redesigned
    A peer-reviewed review describes it as a 26-residue synthetic amphipathic alpha-helical analog of a cecropin A and melittin hybrid, picked out of a rationally designed peptide library. Cecropin comes from moth immunity and melittin from bee venom, and hybrids of the two have been a standard starting point in this field for decades because they keep the antibacterial activity while losing some of the damage to human cells.
  2. 02
    Charge finds the bacteria, grease does the damage
    The sequence is packed with lysine, which carries positive charge, and the helix separates those charges onto one face and greasy residues onto the other. Bacterial membranes are more negatively charged on the outside than human cell membranes are, which is what gives the peptide its selectivity. It binds, inserts and breaks the barrier.
  3. 03
    Resistance is harder, not impossible
    Changing a membrane's basic electrical character is a much larger evolutionary ask than changing one protein, which is the standing argument for this whole class. The developer also describes activity against biofilms. Neither claim means resistance cannot emerge, and no long-term resistance surveillance for this product has been published.
  4. 04
    What that produced in people, and the part to read twice
    In the phase 3 against silver sulfadiazine, clinical response at day 8 was 90.4 percent against 78.7 percent. Bacterial clearance at the same visit was 24.0 percent against 46.0 percent, in the comparator's favor, and the same gap appeared at day 5. The wounds looked better while the cultures looked worse. The later placebo-controlled trial put complete healing at day 15 as its primary endpoint and met it, 64.3 percent against 43.1 percent, with a further gap by day 21, 73.5 percent against 56.9 percent, P equals 0.0018, and bacterial control improved too. That is the strongest argument that the first result was about how good the comparator is rather than how bad this is.
Pathway
THE PEPTIDE
Peceleganan (PL-5)
ACTS ON
The bacterial cell membrane, breached rather than inhibited
RESULT
Complete healing at day 15, the primary endpoint: 64.3 percent against 43.1 percent placebo
RESULT
Clinical response 90.4 percent against 78.7 percent at day 8

A schematic of the compound's mechanism, not a diagnostic image.

03

What else is it used for?

Each use below carries its own evidence level. Approved means regulators have cleared it for that purpose. Investigational means it is in trials. Early research means it is being studied and is not established.

  • Wound infections secondary to first-degree or superficial second-degree burns and scalds, caused by three named organisms: the approved Chinese indication, in fullClinical use
  • Mild infected burn wounds against placebo, the phase 3b indicationpeer-reviewed-human
  • Diabetic foot ulcer infection, the subject of a registered phase 2 with United States sitestrial-protocol
  • Broader drug-resistant wound infection, which the developer markets but which the approved indication does not covernone

The published record

Research index

5

Papers about Peceleganan (PL-5) · this compound only

Searched: peceleganan.

Left out: PL-5 (a short code shared with unrelated compounds, kept for the trial search only); Puyike (a brand name, which returns commercial coverage rather than research); 培西加南 (the Chinese name, which this research database indexes very little of); KWKSFLKTFKSAAKTVLHTALKAISS (the sequence, which does not appear in titles or abstracts); cecropin (the insect peptide it was partly derived from, with its own large literature); melittin (the bee venom peptide it was partly derived from, with its own large literature); antimicrobial peptide (the whole drug class); silver sulfadiazine (the comparator drug, which has its own burn care literature); 850761-47-6 (a CAS number from a database whose other details for this compound are wrong).

4 papers tagged human · 3 not reviews or lab · 3 clinical trial publications

1 registered trials · none with posted results

Furthest stage reached: Approved outside the US, China

Compare this against the whole library →

In animals0
In the lab0
Reviews0
Senior author shareSpread across many groups

Evidence summary

Counted from Europe PMC indexing, not read by a person; a human tag can land on reviews, commentary or lab papers; clinical trial publications is the narrower count. A preprint and its journal version count once.

Peceleganan (PL-5) vial rendering
Compound field notes

At a glance

Four things to know about Peceleganan (PL-5)

01

Evidence

Clinical use

02

Category

Healing and recovery

03

Common vial

Varies

04

Half-life

Not measured, and not the right question

04

How much, and do you cycle it?

The range, and whether you take breaks.

2 parts per thousand spray, once daily (trials), once daily for up to 14 days (trial schedules). A short daily course, 8 to 14 days Trial dose

Both late-stage trials ran a fixed course and stopped: 8 days in the phase 3 and 14 days in the phase 3b. It is treatment for an acute infection rather than something taken on an ongoing basis, and no published study has run it longer.

Compare this against the whole library →

05

How long does it stay in the body?

The half-life, and where the figure comes from.

Not measured, and not the right questionNo figure

No circulating half-life has been published, and the trial that looked found nothing to measure: in the placebo-controlled phase 3b, blood concentrations stayed below the lower limit of quantification throughout 14 days of once-daily use. A drug that does not reach the blood in measurable amounts has no meaningful plasma half-life. How long it stays active on the wound surface is the question that would matter, and that has not been published.

You can compare this against the whole library to see where it sits.

06

How is it given?

Dosing context and source notes.
No draw available

Supplied as a ready-made solution, so there is nothing to mix.

Reported dose: 2 per thousand per dose. Wei et al., Peceleganan Spray for the Treatment of Skin Wound Infections: A Randomized Clinical Trial, JAMA Network Open 7(6):e2415310

Sprayed onto the wound, not injected and not swallowed. Both published late-stage trials used a 2 parts per thousand spray, written 2 permille, applied once daily. The phase 3 ran treatment for 8 days against 1 percent silver sulfadiazine cream; the phase 3b ran once daily for 14 days against placebo. An earlier phase 2b compared 1, 2 and 4 parts per thousand, and 2 is the strength carried forward and approved. The calculator cannot draw a concentration applied to a wound surface, so there is no milligram figure to convert.

07

How do you store it?

Before mixing, and after.

Room temperature, out of light. Cap it tight after each use.

Peceleganan (PL-5) ships as a cream, gel, or serum. Keep it at room temperature away from sun and heat unless the label says otherwise. Refrigerating an emulsion can split the texture. Watch for color, smell, or separation changes and stop using it if any appear.

08

What are the side effects and cautions?

Known cautions and warnings for this compound.

Solubility, computed: 31% charged residues, 46% hydrophobic. Water usually sufficient.

A first-pass rule from peptide manufacturers' guidance. It does not account for disulfide bridges, salt form or how the powder was dried, and it predicts what should be easy rather than what will happen in your vial.

Who should avoid it

Check these before anything else.
  • Any use outside the approved Chinese indication or a clinical trial, since it is not approved in the United States or Europe
  • Treating it as an antibiotic substitute for a deep or systemic infection, because it is a topical spray with no detected systemic absorption
  • Assuming it clears bacteria better than standard care, which the phase 3 found it did not

Stop and get help

These are emergencies. Seek care.
  • Spreading redness, fever or any sign the infection is moving beyond the wound
  • Any allergic reaction, meaning rash, swelling of the face or lips, or trouble breathing
  • A wound that worsens rather than improves over the first few days

Common effects

Expected, and usually mild.
  • Application-related adverse events comparable to silver sulfadiazine cream in the phase 3.
  • No detectable blood levels during treatment in the placebo-controlled phase 3b.

Where this page says nothing is established, that means nobody has studied it, not that a compound is safe.

09

Is Peceleganan (PL-5) approved?

And where the numbers on this page come from.

Not approved, but legal to obtain. Peceleganan (PL-5) has no FDA approval, and it can be prescribed or prepared by a compounding pharmacy in the United States. It is approved in China, but not in the United States.

What has happened recently

Approved in China, approved nowhere else. China's National Medical Products Administration approved peceleganan spray in June 2026 under approval number H20260037, for wound infections secondary to first-degree or superficial second-degree burns and scalds caused by three named bacteria: Staphylococcus epidermidis, Staphylococcus haemolyticus and Acinetobacter baumannii. That is a narrower indication than the general drug-resistant wound infection framing used in press coverage. It is not FDA-approved and not approved in Europe. United States clinical development exists but is early: a registered phase 2 in mild infections of diabetic foot ulcers lists sites in California and Florida. The developer is a Jiangsu company and the Chinese commercialization rights sit with a large domestic pharmaceutical group. The indication wording here comes from that group's own interim report rather than from the regulator's record, which was not read at source during this review.

Guides for this compound

Sources

  • Wei et al., Peceleganan Spray for the Treatment of Skin Wound Infections: A Randomized Clinical Trial, JAMA Network Open 7(6):e2415310(2024)
    The phase 3 trial, read for the full result including the part that is usually left out. Multicenter, open-label, randomized, at 37 hospitals in China from 23 August 2021 to 16 July 2022. Of 804 screened, 570 were randomized 2 to 1 to 2 permille peceleganan spray or 1 percent silver sulfadiazine cream; 558 completed, 375 of 381 in the treatment group and 183 of 189 in the control. Mean age 48.6 years, 64.7 percent men. On day 8 clinical efficacy was 90.4 percent, 339 patients, against 78.7 percent, 144 patients, P below .001; on day 5 it was 59.2 percent against 49.2 percent, P equals .03. Bacterial clearance went the other way: on day 8, 80 of 334 patients, 24.0 percent, in the treatment group against 75 of 163, 46.0 percent, in the control group, P below .001; on day 5, 55 of 334, 16.5 percent, against 50 of 163, 30.7 percent, P below .001. Trial registration ChiCTR2100047202. Published 11 June 2024.
  • Wei et al., Efficacy and Safety of PL-5 Topical Spray for Burn Wound Infections: A Multicenter, Randomized, Double-Blind, Placebo-controlled, Phase IIIb Clinical Trial, Burns and Trauma, 6 October 2026(2026)
    The placebo-controlled trial published after this compound was approved, read via a reproduction because the journal page could not be opened here. It is a multicenter, randomized, double-blind, placebo-controlled phase 3b across 23 centers in China, led from a Shenzhen hospital, randomizing 348 adults with mild infected burn wounds to 2 permille peceleganan spray or placebo once daily for 14 days, with complete wound healing on day 15 as the primary endpoint. Complete healing on day 15 was 64.3 percent against 43.1 percent; by day 21 it was 73.5 percent against 56.9 percent, P equals 0.0018; comprehensive efficacy was 63.1 percent against 41.9 percent. Bacterial control improved against placebo, and blood concentrations stayed below the lower limit of quantification, indicating no systemic absorption. The day 8 healing assessment did not separate the groups. Published 6 October 2026 in Burns and Trauma. The digital object identifier is printed inconsistently across the press coverage, so it is not reproduced here; the journal, title, authors and date are given instead.
  • Antimicrobial Peptides for Diabetic Foot Ulcers and Infections: Current Evidence and Translational Perspectives(2026)
    A peer-reviewed review of antimicrobial peptides in diabetic foot disease, read for the independent description of what this molecule is and for its reading of the trial evidence. It states that PL-5, peceleganan, is a 26-residue synthetic amphipathic alpha-helical analog of a cecropin A and melittin B hybrid peptide selected from a rationally designed peptide library. It also records the phase 2b comparison of 1, 2 and 4 permille PL-5 against 1 percent silver sulfadiazine, noting that clinical efficacy rates were higher across the PL-5 groups at days 5 and 8 while bacterial clearance rates did not differ significantly from silver sulfadiazine at either visit, and that no severe treatment-related adverse events occurred. Note the distinction from the phase 3, where bacterial clearance did differ and favored the comparator.
  • Sino Biopharmaceutical Limited, Interim Report 2026(2026)
    The commercialization partner's interim report, read as a company document and cited for the approval and the exact indication wording. It records that the product received approval for marketing by the National Medical Products Administration in June 2026 for the treatment of wound infections secondary to first-degree or superficial second-degree burns and scalds caused by Staphylococcus epidermidis, Staphylococcus haemolyticus and Acinetobacter baumannii. It describes peceleganan as the first non-antibiotic antimicrobial agent of a novel design, working on a membrane discrimination mechanism by disrupting the barrier function of bacterial biofilm systems, and names it among the group's recently approved products.
  • Jiangsu ProteLight Pharmaceutical and Biotechnology, announcement of the phase 3 publication(2024)
    The developer's own announcement of the phase 3 publication, read as a company document and cited for the development history. It records that the trial results were published in JAMA Network Open in June 2024, names the project code PL-5, and describes the study as the first successful phase 3 trial of an antimicrobial peptide drug for wound infections to be published in a major international journal.
  • Registry record NCT06189638, PL-5 in mild infections of diabetic foot ulcers, read via a reproduction(2026)
    The registry record for the United States phase 2, read via a search-engine reproduction because ClinicalTrials.gov could not be opened during this review. It is titled a phase 2 study to evaluate efficacy and safety of AMP peptide PL-5 in mild infections of diabetic foot ulcers, lists three sites in the United States, in California and Florida, and cites both the JAMA Network Open phase 3 and the earlier phase 2b as background. This is the record that shows development is not confined to China.
  • Patent and drug intelligence database entry, Peceleganan(2026)
    A drug database entry, cited here only because it is wrong in a way worth recording. It gives the developer, the approval date of 17 June 2026 in China, the molecular formula C138H226N36O34 and a CAS registry number, but tags the mechanism as penicillin-binding protein inhibitors. Every primary description of this compound, including the developer's and the commercialization partner's, describes membrane disruption rather than inhibition of a bacterial enzyme. The formula and date are usable; the mechanism tag is not.

Beyond these, 6 records are indexed for this compound. Browse the records